Core Viewpoint - Hims & Hers Health Inc. faces legal threats from Novo Nordisk after announcing plans to launch a generic version of the weight loss drug Wegovy, leading to significant stock price volatility [3][4]. Group 1: Company Actions and Market Response - Hims & Hers plans to introduce a generic version of Wegovy, containing the same active ingredient, semaglutide, with an initial subscription price of $49, increasing to $99 after the first month [3]. - Following the announcement, Hims' stock surged by 15% on Thursday but fell by 3.8% by the end of the day and dropped another 6.5% in early trading on Friday, reaching a 12-month low [3][4]. - The company previously launched a semaglutide injection, capitalizing on a regulatory loophole that allows competitors to sell related formulations if the patented drug is in short supply [4]. Group 2: Legal and Regulatory Challenges - Novo Nordisk claims Hims' actions are illegal and pose risks to patient safety, citing previous warnings from the FDA regarding Hims' misleading advertising of GLP-1 generics [4]. - Hims argues that its generic pill will be personalized based on patient needs, which they believe legitimizes their offering [4]. Group 3: Analyst Perspectives - Analysts have mixed views on Hims' stock, with Michael Cherney rating it as "in line with the market" and suggesting potential plans to launch generics for Eli Lilly's weight loss drugs [5]. - Barclays analyst James Gordon highlights the $49 Wegovy generic as a new threat to Novo Nordisk, noting concerns about regulatory compliance and clinical efficacy of such products [5].